Yellow fever virus in Brazil
Between July 1, 2017, and Jan 30, 2018, 233 cases of yellow fever were reported in Brazil, including 81 deaths. On Jan 25, Brazilian health authorities began a campaign with the aim of vaccinating 23·8 million people across the states of Rio de Janeiro, São Paolo, and Bahia using a dose fractionation strategy. 
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On Jan 3, 2018, WHO announced the prequalification of a typhoid c o n j u g a t e v a c c i n e ( T C V ) manufactured by the Indian firm Bharat Biotech. The decision was expected after last year's endorsement by WHO's Strategic Advisory Group of Experts (SAGE) on immunisation, which recommended that the TCV be introduced for infants and children older than 6 months in typhoidendemic countries.
SAGE suggested that places with high burdens of disease or high rates of drug-resistant bacteria should be prioritised. Soon afterwards, the Gavi Alliance stated that it would make US$85 million available for eligible countries who wished to introduce the TCV. Worldwide, there are estimated 12 million cases of typhoid fever every year and around 128 000 deaths.
The vaccine, Typbar-TCV, has been licenced for use in India and Nepal as a single intramuscular injection. The company is able to supply 50 million doses of the vaccine per year, but there are plans to raise its capacity to around 200 million doses. Other manufacturers are also developing TCVs. These vaccines are expected to become available over the next few years.
Andrew Pollard (Oxford University, Oxford, UK) led the research team that assessed the TCV. In the phase 2b human challenge study, the vaccine showed an efficacy of 54%. But that was under extremely stringent conditions. Pollard reckons that in the field, efficacy could be as high as 87%. "In places where there is poor water and sanitation, the roll-out of the TCV will lead to a huge reduction in typhoid fever", Pollard told The Lancet Infectious Diseases. "But we have to do this as quickly as possible because drug resistance is a real threat to some of these populations". The emergence of cephalosporin-resistant Salmonella Typhi in south Asia is particularly concerning.
Denise Garrett, director of the Coalition against Typhoid (Washington DC, USA), welcomed the prequalification. "To finally have a vaccine that we can use on children under the age of 2 years is fantastic news", she said. "The idea now is to start advocacy campaigns in the endemic countries and to encourage policy makers to adopt the vaccine". Ongoing trials in Bangladesh, Malawi, and Nepal will eventually result in the vaccination of approximately 85 000 children. "We will follow them over the next few years to really get a measure of the potential population impact of the TCV", concluded Pollard.
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